Bora Pharmaceuticals and Celltrion Asia Pacific, a subsidiary of Celltrion Group, have joined forces to contract manufacture and commercialize a range of oral solid dosage (OSD) drugs across the Asia-Pacific (APAC) region. The range of oral dosage form products will be manufactured at Bora’s Zhunan site, which is one of the largest U.S. FDA and MHRA-approved pharmaceutical production facilities in Taiwan. In addition, the manufactured batches will be used to support Celltrion’s regulatory ...